Modarres-Sadeghi H, Guiloff R J
Department of Neurology, Charing Cross and Westminster Medical School, Westminster Hospital, London.
J Neurol Neurosurg Psychiatry. 1990 Nov;53(11):944-7. doi: 10.1136/jnnp.53.11.944.
Ten consecutive patients with motor neuron disease (MND) who had bulbar symptoms received one or two intravenous doses followed by increasing oral doses of a TRH analogue (RX77368). Similar improvements in speech, swallowing and in tongue and jaw movements were seen after iv and oral administration in nine, five and eight patients respectively. The initial time course of improvement correlated with increasing plasma levels of the drug, but most clinical effects persisted when the levels decreased and became undetectable after 24 hours. The oral solution was tasteless and had no, or minimal, side effects.
连续十位患有球部症状的运动神经元病（MND）患者接受了一或两次静脉注射剂量的促甲状腺激素释放激素类似物（RX77368），随后口服剂量逐渐增加。静脉注射和口服给药后，分别有九名、五名和八名患者在言语、吞咽以及舌头和下颌运动方面出现了类似改善。改善的初始时间进程与药物血浆水平升高相关，但当药物水平下降并在24小时后变得无法检测到时，大多数临床效果仍持续存在。口服溶液无味，且无副作用或副作用极小。
